Literature DB >> 15069045

Ejaculation frequency and subsequent risk of prostate cancer.

Michael F Leitzmann1, Elizabeth A Platz, Meir J Stampfer, Walter C Willett, Edward Giovannucci.   

Abstract

CONTEXT: Sexual activity has been hypothesized to play a role in the development of prostate cancer, but epidemiological data are virtually limited to case-control studies, which may be prone to bias because recall among individuals with prostate cancer could be distorted as a consequence of prostate malignancy or ongoing therapy.
OBJECTIVE: To examine the association between ejaculation frequency, which includes sexual intercourse, nocturnal emission, and masturbation and risk of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Prospective study using follow-up data from the Health Professionals Follow-up Study (February 1, 1992, through January 31, 2000) of 29 342 US men aged 46 to 81 years, who provided information on history of ejaculation frequency on a self-administered questionnaire in 1992 and responded to follow-up questionnaires every 2 years to 2000. Ejaculation frequency was assessed by asking participants to report the average number of ejaculations they had per month during the ages of 20 to 29 years, 40 to 49 years, and during the past year (1991). MAIN OUTCOME MEASURE: Incidence of total prostate cancer.
RESULTS: During 222 426 person-years of follow-up, there were 1449 new cases of total prostate cancer, 953 organ-confined cases, and 147 advanced cases of prostate cancer. Most categories of ejaculation frequency were unrelated to risk of prostate cancer. However, high ejaculation frequency was related to decreased risk of total prostate cancer. The multivariate relative risks for men reporting 21 or more ejaculations per month compared with men reporting 4 to 7 ejaculations per month at ages 20 to 29 years were 0.89 (95% confidence interval [CI], 0.73-1.10); ages 40 to 49 years, 0.68 (95% CI, 0.53-0.86); previous year, 0.49 (95% CI, 0.27-0.88); and averaged across a lifetime, 0.67 (95% CI, 0.51-0.89). Similar associations were observed for organ-confined prostate cancer. Ejaculation frequency was not statistically significantly associated with risk of advanced prostate cancer.
CONCLUSIONS: Our results suggest that ejaculation frequency is not related to increased risk of prostate cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15069045     DOI: 10.1001/jama.291.13.1578

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

1.  Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.

Authors:  Y Wang; J-Q Li; C Shao; C-H Shi; F Liu; Z-Y Yang; J-X Qiu; Y-M Li; Q Fu; W Zhang; W Xue; Y-H Lei; J-Y Gao; J-Y Wang; X-P Gao; J-L Yuan; T-Y Bao; Y-T Zhang
Journal:  Ir J Med Sci       Date:  2011-07-05       Impact factor: 1.568

2.  Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.

Authors:  Qing He; Bang-Hua Liao; Kai-Wen Xiao; Liang Zhou; Shi-Jian Feng; Hong Li; Kun-Jie Wang
Journal:  Int Urol Nephrol       Date:  2018-09-19       Impact factor: 2.370

3.  Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency.

Authors:  Jennifer A Sinnott; Katherine Brumberg; Kathryn M Wilson; Ericka M Ebot; Edward L Giovannucci; Lorelei A Mucci; Jennifer R Rider
Journal:  Eur Urol       Date:  2018-05-18       Impact factor: 20.096

Review 4.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

5.  Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.

Authors:  Anthony H Chavez; K Scott Coffield; M Hasan Rajab; Chanhee Jo
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

6.  Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer.

Authors:  Karen S Sfanos; Brice A Wilson; Angelo M De Marzo; William B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

7.  Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.

Authors:  Jennifer R Rider; Kathryn M Wilson; Jennifer A Sinnott; Rachel S Kelly; Lorelei A Mucci; Edward L Giovannucci
Journal:  Eur Urol       Date:  2016-03-28       Impact factor: 20.096

Review 8.  Prostate cancer: is it time to expand the research focus to early-life exposures?

Authors:  Siobhan Sutcliffe; Graham A Colditz
Journal:  Nat Rev Cancer       Date:  2013-01-31       Impact factor: 60.716

9.  Prostate calculi in cancer and BPH in a cohort of Korean men: Presence of calculi did not correlate with cancer risk.

Authors:  Eu-Chang Hwang; Hyang-Sik Choi; Chang-Min Im; Seung-Il Jung; Sun-Ouck Kim; Taek-Won Kang; Dong-Deuk Kwon; Kwang-Sung Park; Soo-Bang Ryu
Journal:  Asian J Androl       Date:  2009-12-28       Impact factor: 3.285

Review 10.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.